Intellia, Regeneron ace first trial with 'in vivo' CRISPR dr...

The first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the body has yielded impressive results in patients with ATTR amyloidosis, a life-threatening r

Vyndaqel romps away in US, spurring earnings hike from Pfize...

Alnylam gears up for first RNAi therapeutic filing in 2017

US biotech Alnylam says it could file its first product in 2017, a rare disease drug using what has long promised to be a revolutionary approach, RNA interference.